Resmetirom – Selective THR-beta Agonist for NASH / MASH Treatment

Resmetirom is a first-in-class, highly selective oral thyroid hormone receptor-beta (THR-beta) agonist. The drug was developed for the etiotropic and pathogenic therapy of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), accompanied by moderate to advanced liver fibrosis. Its primary mechanism of action involves the targeted activation of THR-beta receptors, which predominate in liver tissue and play a key role in regulating systemic and hepatic lipid metabolism, fatty acid degradation, and maintaining normal hepatocyte function.

The uniqueness of resmetirom lies in its high selectivity, which allows it to purposefully stimulate metabolism in the liver while avoiding the activation of thyroid hormone receptor-alpha (THR-alpha), located in the heart and bone tissue. This minimizes the risks of cardiotoxicity, tachycardia, and osteoporosis. By activating the THR-beta signaling pathway, resmetirom enhances mitochondrial beta-oxidation of fatty acids, stimulates lipophagy, and reduces intrahepatic accumulation of toxic lipids. Clinical studies confirm that the drug not only significantly reduces steatosis (fatty liver) and inflammation but also promotes the regression of liver fibrosis, preventing its transformation into cirrhosis. The drug represents a revolutionary breakthrough in hepatology, offering an effective solution for the management of progressive metabolic liver diseases.

The drug is taken orally once daily. Treatment requires regular monitoring of the lipid profile and assessment of liver status using non-invasive methods or biomarkers.

Wikipedia page
Resmetirom

Indications

Resmetirom is indicated for the treatment of adult patients with the following conditions:

  • Steatohepatitis (NASH/MASH): non-alcoholic steatohepatitis with histologically or clinically confirmed stage 2 or 3 liver fibrosis (moderate to advanced fibrosis).
  • Comprehensive Therapy: used in conjunction with lifestyle modification, a low-calorie diet, and physical activity to optimize metabolic parameters.

Dosage and administration

The resmetirom dosing regimen is adjusted based on the patient's body weight to ensure optimal therapeutic concentrations.

  • Patients weighing less than 100 kg: the recommended dose is 80 mg taken orally once daily.
  • Patients weighing 100 kg or more: the recommended dose is 100 mg taken orally once daily.
  • Administration Method: tablets are swallowed whole, at approximately the same time each day, with or without food.
  • Missed Dose: if a dose is missed, it should be taken as soon as the patient remembers, provided the next scheduled dose is more than 12 hours away. Do not double the dose.
  • Dose Adjustment: modifications may be required when co-administered with strong inhibitors or substrates of certain transporter proteins (such as statins).

The use of resmetirom has limitations and requires caution in decompensated states:

  • Hypersensitivity: known allergy or individual hypersensitivity to resmetirom or any excipients.
  • Hepatic Impairment: severe hepatic impairment (Child-Pugh Class B and C) or decompensated cirrhosis.
  • Pregnancy and Lactation: safety of use has not been established; therapy is not recommended for pregnant women or during breastfeeding.
  • Drug Interactions: requires caution and dose restriction when co-administered with OATP1B1/1B3 inhibitors (e.g., cyclosporine), as they significantly increase resmetirom concentrations.

The side effects of resmetirom are generally mild to moderate and reflect the intensification of metabolic processes:

  • Digestive System: diarrhea (the most frequent symptom, predominantly at the beginning of treatment), nausea, vomiting, and abdominal pain.
  • Biliary System: increased risk of developing cholelithiasis (gallstones) and cholecystitis.
  • Integumentary System: pruritus (itching), urticaria, or a mild, transient rash.
  • Cardiovascular System: transient sensation of palpitations or minor fluctuations in blood pressure.
  • General Symptoms: dizziness, fatigue, and peripheral edema of the lower limbs.

Frequently Asked Questions

Resmetirom is a first-in-class, oral, small-molecule targeted therapy that acts as a highly selective agonist of thyroid hormone receptor-beta ($THR-\beta$) in the liver. These receptors play a central role in regulating hepatic lipid metabolism. By activating $THR-\beta$, resmetirom increases the breakdown of fats within liver tissue, reduces toxic lipid accumulation, decreases inflammation, and helps halt the progression of liver fibrosis.
Resmetirom is indicated for the treatment of adult patients with nonalcoholic steatohepatitis (NASH, also known as metabolic dysfunction-associated steatohepatitis — MASH) who have moderate to advanced liver fibrosis (corresponding to stages F2–F3). The goal of therapy is to resolve liver inflammation and achieve a reduction or regression of fibrosis.
Resmetirom is taken orally once daily at approximately the same time each day, with or without food. The tablet should be swallowed whole. The dosage is typically tailored by a physician based on the patient's body weight (usually 80 mg or 100 mg per day) to ensure optimal therapeutic efficacy.
The most frequently reported side effects when initiating resmetirom are diarrhea and nausea. These symptoms are generally mild to moderate in severity, typically onset within the first few weeks of starting therapy, and tend to resolve over time as the body adapts. If diarrhea becomes persistent or severe, patients should contact their doctor for supportive management.
Yes, through the activation of $THR-\beta$ receptors, resmetirom helps significantly lower levels of "bad" cholesterol (LDL-C) and triglycerides in the bloodstream. However, the substance can increase the concentration of certain plasma-coadministered drugs, particularly statins. It is essential to inform your doctor about all current medications, as a reduction in the statin dose may be required.

List of medicines by active substance

-6%
Resiliva 80 80 mg Everest
View
Everest

Resiliva 80

Resmetirom
80 mg 30 tablets
8000₴ 8539₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00